HAMBURG, Germany – Cognetivity Neurosciences Ltd. has received "two key patent application approvals" from the U.S. and from the EU for its Integrated Cognitive Assessment (ICA) platform, a test for early detection of signs of Alzheimer's disease. "Securing patents in key markets for our technology is a major company milestone and something we've worked very hard to achieve," said Cognetivity's CEO Sina Habibi. "This protection of our unique and innovative technology puts us in a strong position as we move through the final stages of the regulatory process, finalize our clinical product and launch a commercial product within these territories."